Bio-Path (BPTH) News Today $0.12 +0.02 (+23.27%) As of 03:58 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFDA EventsHeadlinesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock BPTH Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Bio-Path: Q2 Earnings SnapshotAugust 14, 2025 | sfgate.comBio-Path Holdings, Inc. (BPTH) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comBio-Path Holdings to Present at Life Sciences Virtual Investor ForumJune 9, 2025 | finance.yahoo.comRoth Capital Lowers Bio-Path (BPTH) PT to $2 Amidst Pipeline Updates, Liquidity ConcernsJune 4, 2025 | msn.comBio-Path Holdings Provides Clinical and Operational UpdateJune 3, 2025 | globenewswire.comBio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025May 22, 2025 | globenewswire.comBio-Path Advances BP1001-A As Potential Obesity Therapy With Positive Preclinical DataMay 3, 2025 | nasdaq.comBio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes PatientsMay 1, 2025 | globenewswire.comBio-Path price target lowered to $9 from $12 at Roth MKMMarch 31, 2025 | markets.businessinsider.comBio-Path reports FY24 EPS ($4.12) vs ($33.63) last yearMarch 29, 2025 | markets.businessinsider.comBio-Path Holdings Reports Full Year 2024 Financial ResultsMarch 28, 2025 | globenewswire.comBio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes PatientsMarch 18, 2025 | globenewswire.comBIO-PATH HOLDINGS Earnings Preview: Recent $BPTH Insider Trading, Hedge Fund Activity, and MoreMarch 7, 2025 | nasdaq.comBio-Path receives new patents for P-ethoxy nucleic acidsFebruary 13, 2025 | markets.businessinsider.comBio-Path provides key clinical updates on BP1001-A, AMLFebruary 13, 2025 | markets.businessinsider.comBio-Path reports positive trial outcomes for cancer treatmentsFebruary 13, 2025 | msn.comBio-Path Holdings Provides Key Clinical UpdatesFebruary 13, 2025 | globenewswire.comBio-Path announces BP1002 trial advances to higher dose cohortFebruary 12, 2025 | markets.businessinsider.comBio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid LeukemiaFebruary 12, 2025 | globenewswire.comBio-Path Holdings Provides 2025 Clinical and Operational UpdateJanuary 10, 2025 | globenewswire.comIs This Penny Stock a Buy After a 180% Rally?December 29, 2024 | msn.comBio-Path Holdings: Promising Preclinical Results for BP1001-ADecember 20, 2024 | markets.businessinsider.comWhy Bio-Path Is Rising In Pre-market?December 19, 2024 | markets.businessinsider.comBio-Path announces preclinical testing of BP1001-ADecember 19, 2024 | markets.businessinsider.comBio-Path Holdings Shares Were On The Rise: What's Going On?December 19, 2024 | benzinga.comBio-Path Rockets To 4-Month High As Obesity Drug Shows Promise For Diabetes: Retail In Celebration ModeDecember 19, 2024 | msn.comBio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin SensitivityDecember 19, 2024 | globenewswire.comBio-Path Holdings Faces Nasdaq Compliance and Strategic ChangesDecember 13, 2024 | tipranks.comBio-Path outlines rationale for development of BP1001-ADecember 12, 2024 | markets.businessinsider.comBio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes PatientsDecember 11, 2024 | globenewswire.comBio-Path Holdings Inc (BPTH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial ...November 21, 2024 | finance.yahoo.comBio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2024 Earnings Call TranscriptNovember 16, 2024 | msn.comBio-Path Holdings, Inc. (BPTH) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | seekingalpha.comBio-Path Holdings Reports Third Quarter 2024 Financial ResultsNovember 15, 2024 | globenewswire.comUncovering Potential: Bio-Path Holdings's Earnings PreviewNovember 15, 2024 | benzinga.comBio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024November 8, 2024 | globenewswire.comBio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesOctober 10, 2024 | globenewswire.comNano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood CancerOctober 10, 2024 | finance.yahoo.comBio-Path Holdings Inc (BPTH) Q2 2024 Earnings Call Highlights: Financial Improvements and ...October 10, 2024 | finance.yahoo.comBio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesOctober 8, 2024 | globenewswire.comBio-Path Holdings Initiates Development of Therapeutic Program for Treatment of ObesityOctober 8, 2024 | globenewswire.comBio-Path Holdings Announces Publication in BiomedicinesSeptember 16, 2024 | markets.businessinsider.comBio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | globenewswire.comWhat Happened With Bio-Path Stock Today?August 21, 2024 | msn.comBio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid TumorsAugust 21, 2024 | markets.businessinsider.comBio-Path Updates Phase 1/1b Study Of BP1001-A In Solid TumorAugust 21, 2024 | markets.businessinsider.comBio-Path Holdings, Inc.: Bio-Path Holdings Reports Second Quarter 2024 Financial ResultsAugust 17, 2024 | finanznachrichten.deBio-Path Holdings, Inc. (NASDAQ:BPTH) Q2 2024 Earnings Call TranscriptAugust 17, 2024 | msn.comBio-Path Holdings Reports Second Quarter 2024 Financial ResultsAugust 15, 2024 | globenewswire.comBio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024August 8, 2024 | globenewswire.com Get Bio-Path News Delivered to You Automatically Sign up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BPTH Media Mentions By Week BPTH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BPTH News Sentiment▼0.001.03▲Average Medical News Sentiment BPTH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BPTH Articles This Week▼00▲BPTH Articles Average Week Get the Latest News and Ratings for BPTH and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Bio-Path and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies VRAX News ENTO News CERO News QLGN News RDHL News SLRX News VCNX News LIPO News PTIX News SPRC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BPTH) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Path With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access